Cargando…
Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed Helicobacter pylori Infection as 14 Days of Bismuth-Based Quadruple Therapy
Background/Aims: Point mutations in the 23S ribosomal RNA gene have been associated with Helicobacter pylori (H. pylori) clarithromycin resistance and bismuth-based quadruple therapy (BQT) is one of the options for the treatment of clarithromycin-resistant H. pylori. Current H. pylori treatment guid...
Autores principales: | Moon, Sang-Gon, Lim, Chul-Hyun, Kang, Hee-Jun, Choi, Arum, Kim, Sukil, Oh, Jung-Hwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369116/ https://www.ncbi.nlm.nih.gov/pubmed/35956057 http://dx.doi.org/10.3390/jcm11154440 |
Ejemplares similares
-
The Comparison of Levofloxacin- and Clarithromycin-Based Bismuth Quadruple Therapy Regimens in Helicobacter pylori Eradication
por: Arj, Abbas, et al.
Publicado: (2020) -
Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant Helicobacter pylori Infection: Effectiveness and Cost-Efficiency
por: Lee, Moon Won, et al.
Publicado: (2022) -
Effects of 14-days bismuth- and tetracycline-containing quadruple therapy with concomitant regimen for the first line Helicobacter
pylori eradication
por: Kazemi Veysari, Arash, et al.
Publicado: (2023) -
Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection
por: Kim, Jeemyoung, et al.
Publicado: (2022) -
Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection
por: Lee, Seong tae, et al.
Publicado: (2015)